Targeted toxins

Arthur E. Frankel, Robert J. Kreitman, Edward A. Sausville

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.

Original languageEnglish (US)
Pages (from-to)326-334
Number of pages9
JournalClinical Cancer Research
Volume6
Issue number2
StatePublished - Feb 2000

Fingerprint

Immunotoxins
Neoplasms
Apoptosis Regulatory Proteins
Pharmacology
Ligands
Peptides
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frankel, A. E., Kreitman, R. J., & Sausville, E. A. (2000). Targeted toxins. Clinical Cancer Research, 6(2), 326-334.

Targeted toxins. / Frankel, Arthur E.; Kreitman, Robert J.; Sausville, Edward A.

In: Clinical Cancer Research, Vol. 6, No. 2, 02.2000, p. 326-334.

Research output: Contribution to journalArticle

Frankel, AE, Kreitman, RJ & Sausville, EA 2000, 'Targeted toxins', Clinical Cancer Research, vol. 6, no. 2, pp. 326-334.
Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clinical Cancer Research. 2000 Feb;6(2):326-334.
Frankel, Arthur E. ; Kreitman, Robert J. ; Sausville, Edward A. / Targeted toxins. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 2. pp. 326-334.
@article{6992b50c0abc45cfbee0693e943a585a,
title = "Targeted toxins",
abstract = "Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.",
author = "Frankel, {Arthur E.} and Kreitman, {Robert J.} and Sausville, {Edward A.}",
year = "2000",
month = "2",
language = "English (US)",
volume = "6",
pages = "326--334",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Targeted toxins

AU - Frankel, Arthur E.

AU - Kreitman, Robert J.

AU - Sausville, Edward A.

PY - 2000/2

Y1 - 2000/2

N2 - Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.

AB - Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0033964059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033964059&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 326

EP - 334

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -